Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Declines By 21.3%

Atyr PHARMA INC (NASDAQ:ATYR) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,070,000 shares, a decrease of 21.3% from the September 30th total of 1,360,000 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 684,000 shares, the days-to-cover ratio is presently 1.6 days.

Atyr PHARMA Stock Up 7.2 %

Shares of Atyr PHARMA stock traded up $0.24 on Tuesday, reaching $3.56. The company’s stock had a trading volume of 503,636 shares, compared to its average volume of 557,523. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.63 and a quick ratio of 7.63. The firm has a market capitalization of $245.68 million, a P/E ratio of -4.04 and a beta of 1.21. The business has a 50-day simple moving average of $2.11. Atyr PHARMA has a 52-week low of $1.08 and a 52-week high of $3.68.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. Sell-side analysts forecast that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ATYR has been the subject of several recent research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price target on shares of Atyr PHARMA in a research report on Wednesday, August 14th. Wells Fargo & Company initiated coverage on shares of Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 target price for the company. Jefferies Financial Group initiated coverage on shares of Atyr PHARMA in a report on Thursday, September 5th. They set a “buy” rating and a $9.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Tuesday.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.